Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes

Biomea Fusion Inc (BMEA) announced an update on their ongoing clinical study.

Biomea Fusion Inc. is moving ahead with a Phase 2 trial called “Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy.” The study tests whether adding icovamenib can help adults whose blood sugar is still too high while on GLP-1 drugs like Ozempic.

The trial evaluates icovamenib, an oral drug candidate, given once daily at 100 mg. It is added on top of a stable Ozempic regimen and compared with a matching placebo to see if it can further improve blood sugar control and safety outcomes.

This is an interventional Phase 2 study with patients randomly assigned in a 2:1 ratio to icovamenib or placebo, both added to Ozempic. The trial is double-blind, so neither patients nor investigators know who gets the active drug, and the main goal is to assess treatment benefit in real-world-like use.

The study is currently recruiting. It was first submitted on March 26, 2026, and the latest update was filed on April 7, 2026, signaling active site set-up and protocol refinement.

For investors, this update highlights Biomea’s push into the large Type 2 diabetes market alongside established GLP-1 players such as Novo Nordisk and Eli Lilly. Positive data could position BMEA as a combination partner and support premium valuation, while trial risk and long timelines mean the stock may remain volatile around milestones.

The Phase 2 trial of icovamenib in patients not at goal on GLP-1 therapy is ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about BMEA’s potential, visit the Biomea Fusion Inc drug pipeline page.